Template:Mecamylamine: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
(3 intermediate revisions by the same user not shown) | |||
Line 2: | Line 2: | ||
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Mecamylamine|{{fontcolor|#6C7B8B|Mecamylamine}}]]''''' | ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Mecamylamine|{{fontcolor|#6C7B8B|Mecamylamine}}]]''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Mecamylamine tablet<sup>®</sup>, Vecamyl<sup>®</sup> FDA Package Insert | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Mecamylamine indications and usage|Indications and Usage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Mecamylamine indications and usage|Indications and Usage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Mecamylamine dosage and administration|Dosage and Administration]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Mecamylamine dosage and administration|Dosage and Administration]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Mecamylamine contraindications|Contraindications]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Mecamylamine contraindications|Contraindications]] | ||
Line 29: | Line 27: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Mecamylamine nonclinical toxicology|Nonclinical Toxicology]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Mecamylamine nonclinical toxicology|Nonclinical Toxicology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Mecamylamine how supplied storage and handling|How Supplied/Storage and Handling]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Mecamylamine how supplied storage and handling|How Supplied/Storage and Handling]] | ||
Line 38: | Line 34: | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Mecamylamine labels and packages|Labels and Packages]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Mecamylamine labels and packages|Labels and Packages]] | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on Mecamylamine | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} ClinicalTrials.gov] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} ClinicalTrials.gov] | ||
|- | |- | ||
|} | |} |
Latest revision as of 18:02, 12 March 2014
Mecamylamine |
---|
Mecamylamine tablet®, Vecamyl® FDA Package Insert |
Indications and Usage |
Dosage and Administration |
Contraindications |
Warnings |
Precautions |
Adverse Reactions |
Drug Interactions |
Use in Specific Populations |
Overdosage |
Description |
Clinical Pharmacology |
Nonclinical Toxicology |
How Supplied/Storage and Handling |
Patient Counseling Information |
Labels and Packages |
Clinical Trials on Mecamylamine |
ClinicalTrials.gov |